IV immunoglobulin
Phase 2
IV immunoglobulin is one of 2 therapeutic programs targeting Systemic Inflammation. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
2 competitors in Systemic Inflammation
#DrugCompanyPhaseTrials
1Fostemsavir
GSKPhase 2
IV immunoglobulin
NNational Institute of Neurological Disorders and Stroke (NINDS)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Systemic Inflammation1 trial
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 (IN-PASC)
Enrolling by invitation·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT05350774·45 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for IV immunoglobulin. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]